S. Schey

J. Snowden, J. Cavenagh, G. Cook, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Stem cell harvesting after bortezomib-based re-induction for myeloma relapsing after autologous transplant: results from the BSBMT/UKMF Myeloma X (Intensive) trial.

J. Snowden, J. Cavenagh, G. Cook, 2016 .

Is the revised International staging system for myeloma valid in a real world population?

R. Benjamin, D. Ladon, M. Neat, 2018, British journal of haematology.

Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.

G. Morgan, M. Jenner, F. Davies, 2006 .

Successful treatment of IgM paraproteinaemic neuropathy with fludarabine

R. Hughes, M. Lunn, S. Schey, 1999, Journal of neurology, neurosurgery, and psychiatry.

Home care versus hospital care in patients with multiple myeloma treated with pamidronate.

J. Child, R. Soutar, S. Schey, 2004, International journal of palliative nursing.

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.

G. Morgan, S. Mackinnon, S. Verfuerth, 2001, Cytotherapy.

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

J. Rossi, E. Jaffe, N. Munshi, 2018, Blood.

Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease

É. Oksenhendler, A. Bagg, M. Lim, 2020, American journal of hematology.

Special Report International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

J. Rossi, E. Jaffe, N. Munshi, 2019 .

Survival from multiple myeloma in England and Wales up to 2001

S. Schey, 2008, British Journal of Cancer.

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial

G. Morgan, W. Gregory, J. Cavenagh, 2015, British journal of haematology.

A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies

A. Prentice, D. Warnock, G. Morgenstern, 1999 .

A Novel Medical Treatment of Cushing's Due to Ectopic ACTH in a Patient With Neurofibromatosis Type 1

S. Hodgson, G. Bano, F. Mir, 2012, International journal of endocrinology and metabolism.

The effects of prior induction therapy with melphalan on subsequent peripheral blood progenitor cell transplantation for myeloma.

G. Ahsan, M. Kazmi, S. Schey, 2001, Clinical and laboratory haematology.

Current Clinical Practice: Stem Cell Transplantation for Chronic Lymphocytic Leukaemia: Is this the Way Forward in the New Millennium?

S. Schey, Stephen Schey, 2000 .

The use of intravenous intermediate dose melphalan and dexamethasone as induction treatment in the management of de novo multiple myeloma

R. Ireland, M. Kazmi, A. Lakhani, 1998, European journal of haematology.

The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England.

H. Møller, M. Richards, K. Phekoo, 2006, Haematologica.

Rituximab and thalidomide combination therapy for Castleman disease

K. Ramasamy, M. Tenant‐Flowers, R. Marcus, 2012, British journal of haematology.

A non myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy.

S. Mackinnon, H. Waldmann, D. Linch, 1999 .

Cytomegalovirus colitis after autologous transplantation for multiple myeloma

D. Ramsey, S. Schey, S. A. Schey, 2000, British journal of haematology.

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.

N. Munshi, É. Oksenhendler, K. Elenitoba-Johnson, 2020, Blood advances.

Results of a BNLI randomized trial of G-CSF dose after cyclophosphamide 1.5g/m(2) for progenitor cell mobilization.

D. Linch, Paul D. Smith, R. Pettengell, 1999 .

Donor cell Leukaemia – an unresolved problem

A. Bashey, S. Brown, S. Schey, 1995, European journal of haematology.

Intracytoplasmic inclusions in B prolymphocytic leukaemia: ultrastructural, cytochemical, and immunological studies.

J. Melo, D. Catovsky, S. Schey, 1985, Journal of clinical pathology.

Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma

K. Yong, Laura A Percy, I. Khan, 2013, European journal of haematology.

Bone marrow transplantation and severe hypophosphataemia

S. Schey, M. Crook, 1996, British journal of haematology.

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.

M. Beksac, M. Dimopoulos, P. Sonneveld, 2019, The Lancet. Oncology.

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy

A. Madan, R. Orlowski, H. Avet-Loiseau, 2013, Leukemia.

Real‐world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi‐centre UK experience

R. Benjamin, M. Jenner, K. Ramasamy, 2017, British journal of haematology.

Serum osteocalcin in the management of myeloma.

M. Shearer, A. Williams, S. Schey, 1992, European journal of cancer.

Cost-Effectiveness of Lenalidomide in Multiple Myeloma Patients with 1 Prior Therapy in England and Wales,

Ruth E. Brown, S. Stern, S. Schey, 2011 .

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.

G. Morgan, S. Mackinnon, K. Peggs, 2000, Blood.

The prognostic value of interim positron emission tomography scans combined with immunohistochemical data in diffuse large B-cell lymphoma.

J. D. van der Walt, M. Hutchings, P. Fields, 2005, Haematologica.

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.

J. Garcia-conde, C. Craddock, S. Mackinnon, 2002, Blood.

A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group.

H. Prentice, A. Prentice, D. Warnock, 1999, British journal of haematology.

Lymphadenopathy and splenomegaly in an HIV-infected man.

R. Tedder, M. Zuckerman, M. Sudhanva, 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

TREATMENT OF CML BLAST CRISIS WITH LOW DOSE ARA‐C

S. Schey, 1985 .

Second autologous transplant with cyclosporin/interferon α-induced graft versus host disease for patients who have failed first-line consolidation

M. Kazmi, C. Hoyle, D. Radia, 2004, Bone Marrow Transplantation.

THE BLAST CRISIS OF CHRONIC GRANULOCYTIC LEUKAEMIA: A NEW APPROACH TO TREATMENT

M. L. Greene, S. Schey, S. Ardeman, 1985, British journal of haematology.

The management of Castleman disease

D. Royston, K. Ramasamy, G. Pratt, 2021, British journal of haematology.

Osteosclerotic myeloma and 'POEMS' syndrome.

S. Schey, 1996, Blood reviews.

MYELOSUPPRESSION COMPLICATING COTRIMOXAZOLE PROPHYLAXIS AFTER BONE MARROW TRANSPLANTATION

H. Kay, S. Schey, 1984, British journal of haematology.

A multicentre, open, non‐comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony‐stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation

P. Ganly, R. Marcus, G. Jackson, 2001, British journal of haematology.

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.

A. Dalgleish, P. Fields, R. Knight, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ANTI‐INTERFERON ANTIBODIES IN ALPHA INTERFERON TREATED PATIENTS WITH CHRONIC MYELOID LEUKAEMIA

A. Newland, S. Schey, P. Allen, 1991, British journal of haematology.

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study

G. Morgan, M. Jenner, F. Davies, 2010, British journal of haematology.

Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience.

G. Mufti, K. Ramasamy, S. Mahmood, 2011, Clinical lymphoma, myeloma & leukemia.

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

F. Zhan, K. Anderson, N. Munshi, 2014, Leukemia.

The prognostic influence of mediastinal bulk in pathological stage IIA Hodgkin's disease treated initially with radiotherapy.

K. Maclennan, D. Linch, S. Schey, 1989, Clinical oncology (Royal College of Radiologists (Great Britain)).

Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia

J. Chang, R. Marcus, R. Powles, 2001, Leukemia.

The incidence and outcome of myeloid malignancies in 2,112 adult patients in South East-England.

H. Møller, M. Richards, K. Phekoo, 2006 .

HYPERSENSITIVITY REACTIONS TO HEPARIN AND THE USE OF NEW LOW MOLECULAR WEIGHT HEPARINS

S. Schey, 1989, European journal of haematology.

nonmyeloablative stem cell transplantation In vivo CAMPATH-1H prevents graft-versus-host disease following

G. Morgan, S. Mackinnon, K. Peggs, 2013 .

lymphoproliferative disorders comparison between 2 prospective studies in patients with Nonmyeloablative transplantation with or without alemtuzumab

J. Miguel, C. Craddock, D. Linch, 2013 .

NON-MYELOABLATIVE TRANSPLANTS WITH OR WITHOUT CAMPATH-1H: COMPARISON BETWEEN TWO PROSPECTIVE STUDIES IN PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS.

Dolores, J. Garcia-conde, C. Craddock, 2002 .

Risk of relapse of multiple myeloma following kidney transplantation

R. Benjamin, Sapna Shah, M. Streetly, 2019, Clinical kidney journal.

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.

C. Craddock, S. Mackinnon, K. Peggs, 2004, Blood.

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

G. Morgan, M. Dimopoulos, A. Palumbo, 2014, Leukemia.

Alternate day pomalidomide retains anti‐myeloma effect with reduced adverse events and evidence of in vivo immunomodulation

J. Zeldis, M. Kazmi, M. Streetly, 2008, British journal of haematology.

The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64.

M. Macey, D. McCarthy, M. Streetly, 2006, International immunopharmacology.

Treatment of relapsed and refractory multiple myeloma in the era of novel agents.

H. Goldschmidt, G. Morgan, M. Dimopoulos, 2011, Cancer treatment reviews.

Interview: A lifetime of working to improve outcomes in multiple myeloma

S. Schey, 2013 .

Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma

G. Morgan, A. Palumbo, P. Moreau, 2010, Annals of Hematology.

Thalidomide in the Management of Multiple Myeloma

S. Schey, 2002, Hematology.

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.

J. Cavenagh, R. Chopra, A. Davies, 2002, Blood.

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.

P. Sonneveld, M. Chapman, J. Keats, 2018, Blood.

Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta‐analysis

R. Siegert, C. Ramsenthaler, I. Higginson, 2016, European journal of haematology.

An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment.

J. Cavenagh, J. Child, R. Johnson, 2003, Leukemia research.

Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life

T. R. Osborne, I. Higginson, R. Siegert, 2014, BMC Cancer.

What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools

T. R. Osborne, R. Siegert, C. Ramsenthaler, 2012, European journal of haematology.

Symptoms and anxiety predict declining health-related quality of life in multiple myeloma: A prospective, multi-centre longitudinal study

I. Higginson, R. Siegert, C. Ramsenthaler, 2019, Palliative medicine.

The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study

T. R. Osborne, I. Higginson, R. Siegert, 2016, BMC Cancer.

A randomised trial of cyclophosphamide with and without low dose alpha-interferon in the treatment of newly diagnosed myeloma.

A. Newland, A. Williams, S. Schey, 1993, Leukemia & lymphoma.

The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study

G. Cook, D. Marks, S. Feyler, 2007, Bone Marrow Transplantation.

Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease

K. Ramasamy, B. Hazel, S. Mahmood, 2011, British journal of haematology.

Long-term follow-up of an alemtuzumab (CAMPATH-1H) containing reduced intensity allogeneic transplant regimen for non-Hodgkin's lymphoma (NHL).

C. Craddock, S. Mackinnon, K. Peggs, 2002 .

Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial

J. Cavenagh, G. Cook, L. Clifton-Hadley, 2021, British journal of haematology.

Inhibition of PI3K Class IA Kinases Using GDC-0941 Overcomes Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow Microenvironment Enhancing the Efficacy of Current Clinical Therapeutics

F. Farzaneh, K. Ramasamy, Y. Calle, 2023, Cancers.

Endocrinopathy in polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome

C. Anderson, G. Bano, N. Beharry, 2013 .

Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.

D. Dunlop, C. Fegan, D. Cunningham, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

G‐CSF enables completion of tuberculosis therapy associated with iatrogenic neutropenia

L. Cormican, H. Milburn, S. Schey, 2004, European Respiratory Journal.

Economic Evaluation of Lenalidomide Combined with Dexamethasone for the Treatment of Multiple Myeloma in the UK

G. Morgan, A. Shearer, J. Caro, 2008 .

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5

C. Gibson, S. Schey, S. Dhanasiri, 2017, Oncology and Therapy.

Comparison of a specialist haematological malignancy database against a regional cancer registry: case ascertainment and diagnostic accuracy

H. Møller, M. Richards, K. Phekoo, 2002, British journal of haematology.

New treatments for advanced cancer: an approach to prioritization

I. Smith, S. Masters, I. Smith, 2000, British Journal of Cancer.

Recombinant alpha 2B interferon in combination with oral chemotherapy in late chronic phase chronic myeloid leukaemia.

D. Syndercombe-Court, A. Newland, F. Giles, 1992, Leukemia & lymphoma.

Cost–effectiveness of lenalidomide in multiple myeloma

I. Higginson, S. Schey, 2010, Expert review of pharmacoeconomics & outcomes research.

Life-threatening motor neurotoxicity in association with bortezomib.

S. Gupta, G. Mufti, S. Devereux, 2006, Haematologica.

Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial

J. Cavenagh, G. Cook, L. Clifton-Hadley, 2021, British journal of haematology.

Flexural eruption in two hospitalized patients

R. Selway, D. Creamer, S. Walsh, 2013, Clinical and experimental dermatology.

The “Handfoot Syndrome” occurring with chronic administration of Etoposide

M. Summerhayes, S. Schey, J. Cooper, 1992, European journal of haematology.

Development and validation of the Myeloma Patient Outcome Scale (MyPOS): A quality of life questionnaire for use in the clinical care of people with multiple myeloma

T. R. Osborne, I. Higginson, R. Siegert, 2014 .

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

C. Crawley, J. Cavenagh, G. Cook, 2017 .

United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma

G. Cook, F. Davies, J. Behrens, 2009, International journal of laboratory hematology.

An update of the use and outcomes of the new immunomodulatory agent CC-4047 (Actimid) in patients with relapsed/refractory myeloma.

R. Knight, M. Streetly, S. Rassam, 2003 .

Myeloma: new insights

S. Schey, 2003 .

Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales

Ruth E. Brown, S. Stern, S. Schey, 2013, The European Journal of Health Economics.

Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS)

T. R. Osborne, I. Higginson, R. Siegert, 2015, BMC Cancer.

Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods

I. Higginson, R. Siegert, C. Ramsenthaler, 2017, Quality of Life Research.

Liposomal Daunorubicin (Daunoxome) in Combination with Cyclophosphamide, Vincristine and Prednisolone (COP-X) as Salvage Therapy in Poor-Prognosis Non-Hodgkins Lymphoma

J. Cavenagh, A. Newland, M. Ward, 2001, Leukemia & lymphoma.

Long-term follow-up of an alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant (RIT) regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL)

C. Craddock, S. Mackinnon, K. Peggs, 2004 .

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial

M. Drayson, K. Ramasamy, Sherin Varghese, 2022, Blood Cancer Journal.

What Are the Predictors of Health-related Quality of Life and Cost in Multiple Myeloma? A Meta-analysis

I. Higginson, R. Siegert, C. Ramsenthaler, 2014 .

Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma.

A. Newland, J. Tobias, F. Giles, 1992, European journal of cancer.

The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma

T. R. Osborne, I. Higginson, C. Ramsenthaler, 2017, European journal of haematology.

Fluorescence‐based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells

G. Mufti, K. Ramasamy, Y. Calle, 2012, British journal of haematology.

THE CURRENT USE OF LOW MOLECULAR WEIGHT HEPARINS IN CLINICAL PRACTICE

B. Hunt, S. Schey, Karen Phekoo, 1998, British journal of haematology.

Fluorescence‐based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells

G. Mufti, K. Ramasamy, Y. Calle, 2012, British journal of haematology.

Failure to mobilise is not a poor prognostic factor in myeloma

G. Mufti, K. Ramasamy, A. Mijovic, 2007 .

GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death.

J. Gribben, S. Joel, F. Cotter, 2010, Blood.

Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis - Results From the UK Amyloidosis Treatment Trial

G. Morgan, J. Cavenagh, P. Hawkins, 2009 .

Folate Assays: Serum or Red Cell?

K. Phekoo, S. Schey, J. Dudley, 1997, Journal of the Royal College of Physicians of London.